Replies to post #179574 on Biotech Values

[Bickema]

I figured there wasn't much to take away from the potential deal. After all, as you said, 2-3 Billion is nothing for ABBV.

What I really want to know is what ENTA's plans for their increasingly growing cash position.

I guess it would be smart to conserve capital until first full quarter of sales are in for their lead Hep C drug.